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Atrial fibrillation (AF) is common and its prevalence is 
rising in parallel with increased life expectancy and an 
ageing population. Indeed, it is the most common 
sustained arrhythmia and one in four people over the 
age of 40 years will develop AF within their lifetime.1 
International data reflect a 0.9% population prevalence 
that rises to between 3% and 5% in those aged over 65 
years and to more than 10% in octogenarians.1,2 
Consistent data has been reported from the large 
Renfrew/Paisley cohort of over 15,000 Scottish people.3
AtriAl FibrillAtion And Stroke
Interventional techniques and, to an extent, 
pharmacotherapies have advanced to reduce symptoms 
directly associated with AF burden. However, the 
prevention of thromboembolic complications (primarily 
stroke) remains the over-riding priority. In the 
Framingham study, individuals with AF were at between 
four- and five-fold greater risk of stroke than those 
without.4 This risk is further amplified in the context of 
additional risk factors including, but not limited to, 
diabetes mellitus, systemic hypertension or heart failure. 
In those aged 80–89 years, AF is responsible for just 
under 25% of all strokes.4 
Patients who suffer a stroke in the context of AF are 
more likely to die or suffer permanent disability. In an 
illuminating study performed prior to the advent of 
thrombolysis for the treatment of stroke, Lin et al. 
observed a 30-day mortality of 14% in patients with 
strokes occurring in the absence of AF, while 25% of 
those with AF-associated stroke were dead at 30 days. 
Furthermore, survivors of AF-related stroke had more 
recurrent cerebral ischaemic events and greater disability 
than those with non AF-associated stroke.5 
VitAmin k AntAgoniStS
Since the 1950s, vitamin K antagonists (coumarin and its 
derivatives, primarily warfarin) have been the mainstay 
for use in oral anticoagulant therapy. They are highly 
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effective in the reduction of ischaemic stroke in patients 
with AF, reducing the risk of stroke by 64% in comparison 
to placebo and by 37% when compared with anti-
platelet therapy.6 Further, the anticoagulant effect of 
warfarin is readily reversed by the administration of 
vitamin K and its anticoagulant effect is easily measured 
using the International Normalised Ratio (INR). Despite 
these favourable properties, warfarin has significant 
constraints that have caused problems with its use and 
limited its uptake even in groups at high risk for 
thromboembolic complications of AF. 
Scoring systems such as the CHADS2 (congestive heart 
failure, hypertension, age, diabetes mellitus, stroke or 
transient ischaemic attack [TIA] or thromboembolism) 
and CHA2DS2-VASc (age 65–74, female, vascular disease) 
risk prediction models (Tables 1A and B and 2A and B) 
for thromboembolic risk in AF have been developed and 
validated.7 They have been incorporated into major 
national8,9 and international10,11 guidelines with the 
recommendation that patients at moderate or high risk 
of stroke should be anticoagulated (Figure 1). 
Warfarin is under-prescribed
Prescription and compliance with anticoagulation 
therapy remain disappointingly low. Notably, the Euro 
Heart Survey of AF patients revealed that only 67% of 
patients eligible for anticoagulation received this therapy 
and further concern remains that ‘real world’ prescribing 
is likely to be even lower.12,13 Reasons cited for the 
under-prescription of anticoagulants consistently include 
fear of precipitating bleeding.  Although this can be a 
valid concern, it may also be overstated. Furthermore, 
the elderly are under-represented in anticoagulant 
treatment and are the very group who stand to benefit 
the most.14 
CHADS2 score Patients 
(n=1,733)
Adjusted stroke 
rate %/year
0 120 1.9
1 463 2.8
2 523 4.0
3 337 5.9
4 220 8.5
5 65 12.5
6 5 18.2
tAble 2A CHADS2 score and stroke rate. Adapted from 
the European Society of Cardiology guidelines for the management 
of atrial fibrillation (2010).10
CHADS2 score Patients 
(n=7,329)
Adjusted stroke 
rate %/year
0 1 0
1 422 1.3
2 1,230 2.2
3 1,730 3.2
4 1,718 4.0
5 1,159 6.7
6 679 9.8
7 294 9.6
8 82 6.7
9 14 15.2
tAble 2b CHA2D2-VASc score and stroke rate
CHADS2 risk factor Score
Congestive heart failure 1
Hypertension 1
Age >75 years 1
Diabetes mellitus 1
Stroke or transient ischaemic attack 2
tAble 1A CHADS2 score criteria
CHADS2VASc risk factor Score
Congestive heart failure or left ventricular 
ejection fraction <40%
1
Hypertension 1
Age >75 years 2
Diabetes mellitus 1
Stroke/transient ischaemic attack/
thromboembolism
2
Vascular disease (prior myocardial 
infarction, peripheral arterial disease, aortic 
plaque.
1
Age 65–74 years 1
Sex category (female) 1
tAble 1b CHA2D2-VASc score criteria
letter Clinical characteristic Points 
awarded
H Hypertension 1
A Abnormal liver function and 
abnormal renal function 
(1 point each)
1 or 2
S Stroke 1
B Bleeding 1
L Labile international normalised ratios 1
E Elderly (e.g. age >65 years) 1
D Drug or alcohol misuse 
(1 point each)
1 or 2
tAble 3 HAS-BLED scoring tool for the assessment of 
bleeding risk. From European Society of Cardiology guidelines for 
the management of atrial fibrillation (2010).10
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The HAS-BLED scoring tool for bleeding risk (Table 3) 
has also been incorporated into clinical guidelines to 
assist in anticoagulation decisions but it should be 
recognised that many of the risk factors for bleeding 
(including advancing age and previous stroke) are also 
strongly associated with thromboembolic stroke. 
Maintaining therapeutic anticoagulation with 
warfarin is challenging
To achieve maximal therapeutic benefit for the prevention 
of ischaemic stroke it is important to achieve an INR of 
greater than two. However, exceeding an INR of 3.0 does 
not provide additional protection from ischaemic events 
but does result in a progressive increase in the likelihood 
of intra-cerebral haemorrhage.15 Achieving a stable, 
therapeutic INR may be easier in some patients than 
others but warfarin dosing can be a challenge and is 
influenced by genetic and dietary factors as well as 
concomitant medication. Gladstone et al. illustrated both 
the under-use of anticoagulants in patients with AF and 
the concerning proportion of patients receiving 
anticoagulation but with sub-therapeutic INR. In patients 
known to have AF presenting with a stroke, 39% of 
patients were receiving anticoagulant treatment (all 
warfarin) but only a quarter of the anticoagulated patients 
had an INR within the therapeutic range. Although the 
group with AF who presented with a subsequent stroke 
or TIA were more likely to be receiving an anticoagulant 
(57%), less than a third of these patients had an INR 
within the therapeutic range at presentation.16 
Morgan and colleagues followed a group of over 6,000 
Welsh patients with non-valvular AF. They demonstrated 
that in patients with AF at moderate or high risk for 
stroke, warfarin therapy is only effective at reducing the 
incidence of stroke if the target INR is achieved over 
70% of the time. This is not often achieved in clinical 
practice. Furthermore, treatment with warfarin but with 
poor control (target INR achieved <30% of the time) 
appeared to be harmful.17 
Therapeutic anticoagulation with warfarin is not 
immediate
There is frequently a delay in achieving a therapeutic 
INR after recognition of the need for anticoagulation in 
patients with AF. This stems from the pharmacokinetics 
of warfarin and the requirement for loading doses 
before a stable therapeutic INR is achieved. In some 
instances, local requirements for warfarin therapy to be 
initiated via a dedicated anticoagulation clinic contribute 
to further delay. These factors may conspire to provide 
further time for left atrial thrombus to develop in the 
fibrillating heart. Irrespective of the ease and timing of 
achieving a stable INR and dosing regimen, warfarin 
therapy always requires monitoring. Regardless of age, 
this is inconvenient for the patient and is cumbersome 
and expensive for healthcare systems. 
Dabigatran Rivaroxaban Apixaban
target Factor IIa Factor Xa Factor Xa
Dosing Twice daily Once daily Twice daily
Half-life (h) 12–17 5–13 8–13
Renal excretion (%) 80 33 25
Drug interactions Potent inhibitors of 
P-glycoprotein (P-gp), reduce 
dose with verapamil, avoid 
dronedarone
Potent inhibitors of cytochrome 
P450 3A4 (CYP3A4) or 
P-glycoprotein (P-gp)
Potent inhibitors of P450 3A4 
(CYP3A4) or P-glycoprotein 
(P-gp)
tAble 4 Profiles of novel oral anticoagulants currently available. Adapted from Wisler and Becker (2012).32
figuRe 1 Clinical flowchart for the use of oral anticoagulant 
for stroke prevention in atrial fibrillation. From the European 
Society of Cardiology guidelines for the management of atrial 
fibrillation (2010).10
No
No
Yes
Yes
1 other risk factor*
Oral anticoagulant
Oral anticoagulant 
(or aspirin)
Nothing (or aspirin)
CHADS2 score >2
>2 other risk 
factors*
No Yes
No Yes
Age >75 years
*Other clinically relevant non-major risk factors: Age 65-
74, female sex, vascular disease (as CHA2DS2-VASc).
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noVel orAl AntiCoAgulAntS
The search for novel oral anticoagulants has been 
motivated by the drawbacks associated with warfarin. 
The pharmaceutical industry has been extremely 
competitive in the search for the ideal oral anticoagulant. 
Arguably, the perfect agent would have a rapid onset of 
action and predictable efficacy without the requirement 
for routine monitoring. It would protect from 
thromboembolism at least as well as warfarin and its 
haemorrhagic risk profile would be at least as safe, with 
the means to rapidly reverse its effect if required.
Ximelagatran was the first novel direct oral thrombin 
inhibitor to reach late phase trials and was granted 
approval for human use in several countries. It was 
hoped that this drug would replace warfarin but, after 
a considerable investment of time and finance, 
Ximelagatran was withdrawn in 2006 after significant 
hepatotoxic effects were observed. 
Subsequent development proceeded and novel oral 
anticoagulants including dabigatran etexilate, rivaroxaban 
and apixaban are now available (Table 4). Furthermore, 
they are now supported by randomised controlled trial 
data to support their use in the prevention of 
thromboembolism in patients with AF.18–20 Although 
developed with the same goal, the mechanisms of action, 
pharmacokinetic and pharmacodynamic profiles vary 
sufficiently that they may allow, or perhaps even require, 
tailoring of the choice of therapy depending on specific 
patient characteristics and requirements. Indeed, 
randomised controlled data reinforce this point although 
no direct comparison of these new agents has been 
performed, nor is this likely to occur. The three major 
novel oral anticoagulants currently available will be 
reviewed individually. It should be considered, however, 
that warfarin may remain the most appropriate treatment 
for a large number of patients with AF, particularly those 
already maintained with a stable regime and with an 
infrequent, convenient INR monitoring system in place. 
Other novel oral anticaogulants, including edoxaban, 
darexaban and betrixaban continue in development but 
detailed discussion of these agents is outside the scope 
of this review.
Dabigatran etexilate
Unlike rivaroxaban and apixaban, which both act to 
inhibit the coagulation cascade via antagonism of factor 
X, dabigatran is a direct thrombin (factor II) inhibitor. 
Administered as a prodrug, dabigatran etexilate is 
metabolised by plasma and liver esterases to the active 
moiety, dabigatran. This is a competitive, reversible 
antagonist of thrombin that reaches its peak plasma 
activity between 30 minutes and two hours after oral 
administration. It has a half-life of between 12 and 17 
hours with approximately 80% of the dabigatran excreted 
unaltered by the kidneys. Based upon this and other 
pharmacokinetic data, its effects have been examined 
using twice daily dosing regimens without coagulation 
monitoring.21 It should be used with caution in patients 
receiving inhibitors of P-glycoprotein (quinidine, 
verapamil, amiodarone, clarithromycin). Although the 
combination of dronedarone and dabigtran should be 
avoided, the combination of amiodarone and dabigatran 
does not require dosage alteration. The co-administration 
of potent inducers of P-glycoprotein such as phenytoin, 
carbamazepine, St John’s wort and rifampicin should be 
avoided (Table 3). The use of dabigatran etexilate should 
be avoided in patients with an estimated glomerular 
filtration rate (eGFR) of less than 30 mL/min/1.73m2 and 
in patients with severe liver disease.
The effect of dabigatran on thromboembolic 
complications in patients with AF was examined in the 
Randomised Evaluation of Long-term anticoagulant 
therapY (RE-LY) study.18 This trial recruited 18,113 
patients with AF and at least one other risk factor for 
stroke and randomly assigned patients to either dabigatran 
110 mg twice daily (BD), dabigatran 150 mg BD or 
warfarin with a target INR of 2–3. Those patients receiving 
dabigatran were blinded to the treatment dose received 
but warfarin administration was open-labelled. The mean 
CHADS2 score for those recruited was 2.1 and the mean 
age of patients was 71.5 years. Those receiving warfarin 
had an INR within target range for 64% of the time. This 
result is similar to other major trials to include patients 
receiving warfarin but may be greater than achieved 
outside the clinical trial environment.
At a dose of 150 mg BD, dabigatran was associated with 
a significant reduction in ischaemic stroke or systemic 
embolism when compared with warfarin (1.11% per year 
vs 1.69% per year; hazard ratio [HR] 0.66 [confidence 
interval (CI) 0.53–0.82]; p<0.001), while the result at the 
110 mg BD dose was not significantly different to warfarin. 
Of note, the converse dose-effect was noted when 
bleeding complications were assessed. Compared with 
those receiving warfarin, there was a trend toward fewer 
major haemorrhages in patients receiving dabigatran 150 
mg BD and this effect was statistically significant in those 
administered 110 mg BD. There were 2.87 major bleeding 
episodes per year in those receiving dabigatran 110 mg 
BD and 3.57 episodes per year in those receiving warfarin 
(HR 0.80 [CI 0.70–0.93]; p=0.003). Patients receiving 
dabigatran (both doses) reported a significantly greater 
incidence of dyspeptic symptoms than those taking 
warfarin. Intracranial bleeding is the most devastating 
complication of anticoagulant therapy. Both doses of 
dabigatran were associated with impressive reductions in 
intracranial haemorrhage when compared with warfarin 
(dabigatran etexilate 110 mg BD: HR 0.30 [CI 0.19–0.45], 
p<0.001; dabigatran etexilate 150 mg BD HR 0.40 [CI 
0.27–0.59], p<0.001).22 
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Primarily based upon this trial data, the Scottish 
Medicines Consortium (SMC) has accepted dabigatran 
etexilate for use within National Health Service (NHS) 
Scotland for the prevention of stroke and systemic AF in 
patients with non-valvular AF. They specify that patients 
must also have one or more of the following risk factors 
to qualify: previous stroke, TIA or systemic embolism, left 
ventricular ejection fraction <40%, symptomatic heart 
failure, or age greater than 75 years. Patients aged 65 
years or more qualify if they have diabetes mellitus, 
coronary artery disease or hypertension. They propose 
that the standard dose should be 150 mg BD except for 
patients over the age of 80 who should receive the 
lower dose of 110 mg BD. Based on the evidence from 
RE-LY they also suggest that in those patients younger 
than 80 years, a 110 mg twice daily dose may be 
considered when the thromboembolic risk is low and 
the bleeding risk is high.23
Guidance from the National Institute for Health and 
Clinical Excellence (NICE) is similar and highlights the 
importance of discussion between patient and healthcare 
provider regarding the differences between warfarin and 
dabigatran. Furthermore, they highlight that any decision 
to change from warfarin therapy to dabigatran should be 
made in the context of current INR stability.24
Rivaroxaban
Rivaroxaban is an oral factor Xa inhibitor. Factor Xa is 
pivotal in the coagulation cascade as it is responsible for 
the conversion of prothrombin to biologically potent 
thrombin. Rivaroxaban has an onset of action 
approximately three to four hours after administration 
with predictable pharmacokinetics. Furthermore, there 
is little variation in pharmacodynamics in relation to 
age, sex or body weight. It has a half-life of between five 
and nine hours in healthy individuals and between nine 
and 13 hours in the elderly.25 It is administered as a once 
daily preparation. Around one-third of the drug is 
excreted via the kidneys while the remainder is 
metabolised by the liver. There are no reported food 
interactions with rivaroxaban and the propensity for 
drug interactions is said to be low.26 It is, however, 
recommended that the administration of potent 
inhibitors of cytochrome P450 3A4 (such as antifungal 
agents, chloramphenicol, clarithromycin, protease 
inhibitors) and inhibitors of P-glycoprotein (listed 
above) should be avoided. Rivaroxaban may be cautiously 
co-administered with potent inducers of cytochrome 
P450 3A4 (such as phenytoin, carbamazepine, 
phenobarbital and St John’s wort) as well as inducers of 
P-glycoprotein (also listed above). It should be avoided 
in severe liver disease with coagulopathy, given at a 
reduced dose when the eGFR lies between 15–49 mL/
min/1.73 m2, and avoided completely when renal 
function is worse than this.
Randomised controlled trial data to support the use of 
rivaroxaban in patients with AF comes from the 
Rivaroxaban once daily, Oral, direct factor Xa inhibition 
Compared with vitamin K antagonism for prevention of 
stroke and Embolism Trial in Atrial Fibrillation (ROCKET-
AF). This study compared rivaroxaban 20 mg OD (15 mg 
OD in patients with eGFR 15–49 mL/min/1.73m2) with 
warfarin (target INR 2–3) in 14,264 patients with non-
valvular AF and a CHADS2 score of at least two. This 
comprised a higher risk group than those studied in 
RE-LY, with a mean CHADS2 score of 3.47 and 55% of 
recruits having suffered a previous stroke, TIA or 
systemic embolism. Mean participant age was 73 years in 
both groups. Overall, warfarin therapy was less well 
controlled than in RE-LY with patients falling within 
target INR range for 58% of the time.19
After a mean follow-up of 1.9 years, per-protocol analysis 
revealed an event rate for stroke, TIA or systemic 
embolism of 1.7% per year in the rivaroxaban group and 
2.2% in the group treated with warfarin. Statistical 
analysis confirmed non-inferiority of rivaroxaban versus 
warfarin (HR 0.79 [CI 0.66–0.96]; p<0.001). However, 
superiority of rivaroxaban was harder to demonstrate 
and only became statistically significant when investigators 
analysed the risk of stroke and systemic embolism in 
patients who remained on treatment over the course of 
40 months (HR 0.79 [CI 0.65–0.95]; p<0.015). It was not 
found to be superior to warfarin in the stricter intention-
to-treat analysis (HR 0.88 [CI 0.74–1.03]; p=0.117).
Major bleeding and clinically relevant non-major bleeding 
rates were similar in both groups but, importantly, 
intracranial haemorrhage was less frequent in those 
receiving rivaroxaban (0.49% per year vs. 0.74% per year; 
HR 0.67 [CI 0.47–0.94]; p=0.019).19
The SMC has considered the use of rivaroxaban in 
patients with non-valvular AF and one or more other risk 
factors for stroke. They approve the restricted use of 
rivaroxaban for patients who have poor INR control 
despite evidence that they are complying with a coumarin 
anticoagulant regimen. They also accept its use in patients 
who are allergic to or unable to tolerate coumarin 
anticoagulants. The SMC states that the once daily dosing 
schedule for rivaroxaban may confer some benefits to 
patients. Furthermore, its greater hepatic component to 
elimination may make it more suitable for patients with 
renal dysfunction. They recommend that patients with 
moderate to severe renal dysfunction receive a reduced 
dose of 15 mg once daily.27 The National Institute for 
Health and Clinical Excellence has approved its use for 
the same patients either as a first choice anticoagulant or 
for those previously receiving warfarin.  Again, they 
re-iterate the importance of an informed decision, 
particularly in the context of INR stability if a switch 
from warfarin is considered.28
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Apixaban
Like rivaroxaban, apixaban is a direct factor Xa inhibitor. 
Its onset of maximal action is between one and three 
hours after dosing and it has a half-life of around 12 
hours in healthy volunteers. Therefore twice daily dosing 
is recommended.  Approximately 25% of its excretion 
is via the kidneys and other than interaction with 
potent inhibitors of the cytochrome P450 3A4, there is 
minimal reported drug interaction and advice on 
co-prescription is similar to that for rivaroxaban. It is 
suggested that it can be used with caution in patients 
with eGFR 15–29 mL/min/1.73 m2 and should be 
avoided if eGFR is less than 15 mL/min/1.73 m2. It 
should be noted, however that patients with eGFR 
<25mL/min/1.73 m2 were not included in the phase III 
clinical trial of patients with AF.29 Its use should be 
avoided in patients with severe liver disease or liver 
disease associated with coagulopathy. The standard 
recommended dose is 5 mg BD but this should be 
reduced to 2.5 mg BD in patients over the age of 80 
years, those with a body weight of 60 kg and below, or 
serum creatinine ≥ 132 µmol/L.
The Apixaban for Reduction In Stroke and Other 
ThromboemboLic Events in atrial fibrillation (ARISTOTLE) 
trial provides the randomised controlled trial data to 
inform its use.20 Published in 2011, after RE-LY and 
ROCKET-AF, this trial recruited 18,201 patients with AF 
and at least one risk factor for stroke. Subjects were 
randomised to receive either warfarin (target INR 2–3) 
or apixaban 5 mg BD (2.5 mg BD was given to patients 
recommended for dose reduction based upon the 
factors noted above). The patients recruited were 
marginally younger than those recruited to RE-LY and 
ROCKET-AF (mean age of patients was 70 years) and 
their stroke risk was lower than those in ROCKET-AF, 
but similar to RE-LY (mean CHADS2 score was 2.1); INR 
control was also similar to RE-LY, with patients spending 
an average of 62% of time within the target INR range.
After a median follow-up of 1.8 years, apixaban was 
shown to be superior to warfarin for the primary 
composite end-point of stroke or systemic embolism 
(apixaban: 1.27% per year; warfarin: 1.60% per year; 
hazard ratio (HR) 0.79 [CI 0.66–0.95]; p=0.01 for 
superiority). In addition to this encouraging end-point, 
apixaban treatment was associated with fewer major 
bleeding events (HR 0.69 [CI 0.60–0.80]; p<0.001) and 
fewer haemorrhagic strokes (HR 0.51 [CI 0.35–0.75]; 
p<0.001). Furthermore, all-cause mortality was lower in 
the apixaban group (apixaban: 3.52% per year; warfarin: 
3.94%; HR 0.89 [CI 0.80–0.99]; p=0.047).20 There were no 
unexpected side-effects reported in patients taking 
apixaban and fewer patients stopped taking it than 
warfarin during the trial period.20
Apixaban has a variety of attractive properties, including 
less reliance upon renal excretion compared particularly 
with dabigatran, a good profile for tolerability as well as 
extremely encouraging clinical outcome data. Apixaban 
has had Food and Drug Administration (FDA) approval 
in the United States for the prevention of athrombo-
embolic complications in patients with AF and has 
recently gained approval from both NICE and SMC for 
this indication.
CAutiouS optimiSm For the noVel orAl 
AntiCoAgulAntS
Costs
It is unclear whether the novel oral anticoagulants will 
eventually replace warfarin for thromboembolic stroke 
prevention in AF entirely. As with any new drug, 
particularly those for which there is a large eligible 
population, the financial cost of these agents has been a 
major concern for policy makers. While SMC and NICE 
have approved these three novel anticoagulants as 
outlined above and based upon a series of quality 
adjusted life year assessments, the true costs of these 
drugs remain to be seen. Unsurprisingly, the novel 
anticoagulants are more expensive than warfarin per se 
but there are also substantial costs inherent to current 
INR monitoring infrastructures. The potential for clinical 
benefit holds much greater emphasis for persuading 
policy changes rather than basing arguments simply on 
improved convenience for patients. As well as the 
obvious ethical element to this part of the argument, the 
large costs associated with caring for patients with 
either thromboembolic stroke or a haemorrhagic 
complication of anticoagulation need to be taken into 
account when making public health decisions. 
Monitoring
Although some assays provide information, there is no 
standardised and routinely available method to give a 
quantification of the anticoagulant effect of the novel 
agents.25 It can be crucial or, at the very least, useful to 
understand the degree of anticoagulation at times of 
emergency treatment for haemorrhage, for surgical 
procedures or for the assessment of potential 
anticoagulant overdose.  Although the lack of requirement 
for regular routine anticoagulation monitoring can be 
seen as one of the major advantages of the novel oral 
anticoagulants over warfarin this may also prove to be a 
drawback for a subset of patients for whom achieving a 
stable INR while taking warfarin may, in fact, be non-
compliant with medication. By switching these patients 
to a novel agent without the means to easily assess 
compliance we may, inadvertently, select a non-compliant 
population for (under-) treatment with novel agents.
Reversibility
Unlike the effects of warfarin that may be reversed by 
vitamin K, there is currently no simple antagonist to 
oppose the effects of the novel oral anticoagulants. This 
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remains a concern although the anticoagulant effect of 
the novel agents is shorter acting than that of warfarin. 
Haemodialysis may be used in case of dabigatran 
overdose30 in view of its predominantly renal excretion 
but other measures are non-specific and include the 
administration of exogenous factor VII or fresh frozen 
plasma. The pharmaceutical industry understands that 
this deficiency is one of the major barriers to more 
widespread uptake of the novel agents. Clinical 
development of antagonists continues at pace.31 
ConCluSionS 
The risk of thromboembolism as a consequence of AF is 
well documented and the need for safe, effective and 
convenient anticoagulation is clear. Clinical risk prediction 
tools and their incorporation into major guidelines have 
clarified those who stand to gain the most from 
anticoagulation. However, warfarin prescription remains 
sub-optimal and, even when it is prescribed, many 
patients spend a significant amount of time with a sub-
therapeutic INR. The requirement for regular INR 
monitoring is both inconvenient and costly. 
The advent of novel oral anticoagulants promises a more 
predictable and convenient means to achieve 
anticoagulation. In addition to potential superiority over 
warfarin for the prevention of stroke, they also appear 
to be associated with fewer haemorrhagic effects 
including intracranial bleeding. Warfarin remains tried 
and tested with a wealth of clinical experience behind its 
use. However, understanding the important background 
to the novel agents presents an opportunity to tailor 
anticoagulant treatment, for example in the context of 
renal dysfunction, bleeding risk and concomitant 
medication. The most satisfactory prescribing policy for 
these agents will depend on both financial considerations 
and an appreciation of the positive and negative aspects 
of the novel agents. However, the development of yet 
more preparations, and eventually antidotes, will allow 
treatment of a greater proportion of the large population 
with AF who are currently left overexposed to the 
devastating consequences of thromboembolic stroke.
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